SAN DIEGO, May 30, 2017 (GLOBE NEWSWIRE) -- Amydis Diagnostics, Inc., a preclinical stage, privately-held pharmaceutical company developing proprietary chemistry and innovative approaches to detection of amyloid-related disorders such as Alzheimer’s disease, today announced it has been named to the San Diego Venture Group’s (SDVG) 2017 Cool Companies list. The award honors the San Diego region’s leading technology companies for outstanding performance and for providing leading-edge products and services that fuel growth.
“We are honored to be selected as one of San Diego’s ‘coolest’ companies from so many strong contenders,” said Stella Sarraf, Ph.D., Interim Chief Executive Officer and Founder of Amydis Diagnostics, Inc. “We are proud of our early success and innovation within the diagnostics and dementia space and pleased to represent the very best of the thriving San Diego life science industry.
Amydis was selected for providing game-changing technology that addresses an important problem today regarding the clinical need for diagnostic testing of Alzheimer’s disease in its early stages. The translational potential of the Company's innovative approach using a topical non-invasive ophthalmic diagnostic may help in identifying patients at risk for Alzheimer’s disease and provides a companion diagnostic for disease modifying treatments that may guide therapeutic intervention.
The complete list of San Diego Venture Group’s 2017 Cool Companies is available at https://www.sdvg.org/2017-sdvg-cool-companies-announced/. The 36 regionally based winning businesses will be prominently featured at the SDVG Venture Summit on June 15, which is expected to draw more than 300 attendees including Venture Capital firms from Silicon Valley and Los Angeles.
About San Diego Venture Group
The San Diego Venture Group is a non-profit business organization that fosters relationships and ideas to form, fund and build new ventures. SDVG is helping San Diego evolve into a significant entrepreneurial and venture center. Visit www.sdvg.org for more information.
About Amydis Diagnostics, Inc.
Amydis Diagnostics, Inc. was founded in 2013 to address the urgent medical and clinical need for more sensitive and specific diagnostic testing for Alzheimer’s disease. By significantly improving the effectiveness, accessibility, and ease of testing, our unique technology has the potential to help physicians detect Alzheimer’s disease at its earliest stages, and in doing so, allows appropriate therapeutic options to be developed or pursued. The power of knowing will enable patients and physicians to make the right decisions and change the lives of those impacted by the disease. More information on Amydis can be found at www.amydis.com.